Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia

Neurocrine Biosciences announced FDA Breakthrough Therapy designation for crinecerfont in congenital adrenal hyperplasia, with a new drug application planned for 2024. The company also updated its R&D portfolio, including advancements in gene therapy and muscarinic compounds, and anticipates Phase 2 data readouts for several programs in 2024.